Latest Medical Diagnostics News

Page 1 of 12
Cleo Diagnostics has commissioned three Ella immunoassay instruments at a US laboratory as it prepares to begin the final major clinical testing program for its pre-surgical ovarian cancer test. The approximately 1,470-sample program is intended to support a planned FDA 510(k) submission in the first half of calendar 2027, but no clinical results have yet been reported.
Ada Torres
Ada Torres
12 Nov 2026
Nexsen has secured ISO 13485 certification covering the design, development and manufacture of its StrepSure Group B Streptococcus diagnostic. The milestone strengthens the product’s regulatory and manufacturing platform, but does not yet amount to FDA or TGA approval.
Ada Torres
Ada Torres
2 Nov 2026
Archer Materials has moved its IonQ relationship into early commercial activity and advanced its Biochip towards external testing, but its graphene spin qubit demonstration is taking longer than expected. The company ended September with $A13.0 million in cash and an estimated 4.68 quarters of funding at its quarterly operating burn.
Victor Sage
Victor Sage
28 Oct 2026
Cleo Diagnostics’ prototype ovarian cancer screening test met or exceeded every predefined performance target in a 247-person proof-of-concept study, including among 62 Stage I cases. The result moves the program into larger bridging and expanded studies, but it remains retrospective evidence rather than a validated screening test.
Ada Torres
Ada Torres
21 Oct 2026
An independent, Rhythm-funded economic model estimates its ColoSTAT blood test could avoid 29,427 public-hospital colonoscopies a year and deliver $72.4 million in net annual hospital savings. The figures strengthen Rhythm’s planned case for Medicare reimbursement, but remain modelled estimates rather than evidence from real-world use.
Ada Torres
Ada Torres
7 Oct 2026
Sonic Healthcare delivered a strong FY2026, with underlying net profit up 17% to A$621 million and dividends rising to A$1.08 per share. The next test is whether US efficiencies, LADR synergies and organic growth can offset Swiss fee cuts, a delayed UK contract ramp-up and heavier investment demands.
Ada Torres
Ada Torres
24 Sept 2026
Microba shareholders would own about 67% of an enlarged Genetic Signatures under a proposed all-scrip merger valued at approximately A$51 million. The deal combines roughly A$29.6 million of FY2026 revenue and identifies up to A$3 million in potential annual cost synergies, but remains subject to a long list of approvals.
Victor Sage
Victor Sage
22 Sept 2026
Rhythm Biosciences has completed the first phase of transferring its ColoSTAT blood test to an independent NHS laboratory in England. The milestone supports its international laboratory-partnership strategy, but clinical validation and NHS adoption remain ahead.
Ada Torres
Ada Torres
22 Sept 2026
Cleo Diagnostics has received its first commercial batch of ovarian cancer test kits from Bio-Techne, marking the start of analytical validation critical for its FDA submission planned in early 2027.
Ada Torres
Ada Torres
3 Sept 2026
Rhythm Biosciences marked its transition to commercialisation with first sales of ColoSTAT® and geneType™ tests, despite a 55% increase in loss to $5.93 million. The company expanded market access and secured manufacturing agreements, while NHS England began evaluating ColoSTAT® for bowel cancer screening.
Ada Torres
Ada Torres
27 Aug 2026
Pacific Edge’s draft Medicare Local Coverage Determination for its Cxbladder bladder cancer tests marks a pivotal step toward unlocking a $10.2 billion global market. Despite FY26 setbacks, the company is poised for growth with improved reimbursement prospects and strategic cost management.
Ada Torres
Ada Torres
20 Aug 2026
Archer Materials has pinpointed a capillary blood collection method that matches venous samples in haemolysis levels, advancing its potassium Biosensor development towards integrated clinical testing.
Sophie Babbage
Sophie Babbage
13 Aug 2026

Browse the archive

Full archive